THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Over the first half of 2026, Gelteq has commenced veterinary and pharmaceutical development programs, expanded its delivery platform, and advanced toward future clinical milestones including: "Our ...
Unveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung ...
SHELTON, Conn., July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and ...
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs. “The rapid uptake of YUVIWEL in the United States ...
Windows 10 has been one of the best and most stable versions of the operating system from Microsoft, and it is no wonder that many users have waited to update to the new Windows 11. Despite its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BlackRock today updated shareholders on the progress of its discount management programs (the “Programs”) for certain BlackRock closed-end funds, part of a proactive effort to address trading ...
TransCon - CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growth TransCon CNP monotherapy Week 104 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results